

**MOLECULAR CLONING OF THE HUMAN BRAIN AND GASTRIC
CHOLECYSTOKININ RECEPTOR: STRUCTURE, FUNCTIONAL EXPRESSION
AND CHROMOSOMAL LOCALIZATION[†]**

Joseph R. Pisegna¹, Andreas de Weerth¹, Konrad Huppi², and Stephen A. Wank^{1,*}

¹Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, and

²Laboratory of Genetics, Molecular Genetics Section, National Cancer Institute, National Institute of Health
Bethesda, Maryland

Received October 1, 1992

The receptors for the brain and gastrointestinal peptide, cholecystokinin, can be classified into CCK_A and CCK_B subtypes. Having recently cloned the rat CCK_B receptor, we used its cDNA to isolate the human CCK_B receptor homologue from brain and stomach which encodes a 447 amino acid protein with 90% identity to both rat CCK_B and canine gastrin receptors. Northern hybridization identifies transcripts from stomach, pancreas, brain and gallbladder. The CCK_B receptor gene maps to chromosome 11. Expression of the receptor cDNA in COS-7 cells was characteristic of a CCK_B receptor subtype pharmacology. These data confirm that we have cloned a novel gene for the human brain and stomach CCK_B receptor. © 1992 Academic Press, Inc.

The cholecystokinin (CCK) family of peptides and their receptors are widely distributed throughout the central nervous system (CNS) and gastrointestinal tract (1,2). The receptors for cholecystokinin can be divided into two subtypes on the basis of their affinity for nonsulfated analogues of CCK. CCK_A receptors, having a high affinity only for sulfated CCK-8, are found principally in the gastrointestinal tract and select areas of the CNS while CCK_B (gastrin) receptors, having a high affinity for both sulfated and nonsulfated CCK analogues, are found principally in the CNS and select areas of the gastrointestinal tract (3,4). Recently, highly selective nonpeptide antagonists have been developed which support this subtype classification. Two of the most potent and selective antagonists are L-364,718 for CCK_A receptors (5) and L-365,260, for CCK_B receptors(4). Although the physiological and behavioral role of CNS CCK_B receptors is not well understood, they have been shown to regulate anxiety, arousal, neuroleptic activity (6,7) and opiate induced analgesia (8,9). Outside the CNS, CCK_B receptors regulate gastric acid secretion (10,11) and may play a role in gastrointestinal motility (12,13) and growth of normal and neoplastic gastrointestinal tissue (14).

[†]Sequence data from this article have been deposited with the EMBL/GenBank Data Libraries under Accession No. L04473.

*To whom correspondence should be addressed.

Little is known about the structure and pharmacology of the human CCK_B receptor because of either the difficulty in obtaining fresh tissue or long term culture of normal tissue expressing CCK_B receptors. Tumor cell lines from human small cell carcinoma (14), and lymphoblastic T-cells (JURKAT) (15) have been shown to express CCK receptors with a CCK_B receptor subtype similar to rat, however, some gastric carcinomas (16), leiomyomas (17) and colonic carcinomas (18) appear to have a unique "CCK_B-like" pharmacology and structure. Having recently cloned the rat CCK_B receptor cDNA (19), we used this cDNA to isolate the human CCK_B receptor cDNA and analyze the receptor structure and functional expression.

MATERIALS AND METHODS

TISSUE PROCUREMENT, RNA ISOLATION, AND cDNA SYNTHESIS: Human gastric fundus was obtained as a fresh surgical specimen and immediately frozen in liquid nitrogen. Total RNA was isolated using a low temperature guanidine isothiocyanate method (20) and poly (A)⁺ RNA was isolated using oligo d(T) cellulose chromatography. Oligo d(T) primed cDNA was synthesized using Superscript reverse transcriptase (BRL, Gaithersburg, MD) from one microgram poly (A)⁺ RNA.

ISOLATION OF cDNA CLONES: A human frontal cortex cDNA library in the Lambda ZAP II vector (Stratagene, LaJolla, CA) was screened using a [³²P] random primed probe derived from the rat CCK_B receptor cDNA. Approximately 7.5 x 10⁵ clones were screened at low stringency (3 x 20' washes at 37^o C, 2X SSC/0.1% SDS [1X SSC= .15 M NaCl; 15mM sodium citrate]). Positively hybridizing clones were plaque purified.

PCR CLONING: To obtain a full length human CCK_B receptor cDNA, approximately 5 ng of single stranded human stomach fundus cDNA and the following primers were used in the polymerase chain reaction: a 64 fold degenerate 5' sense primer: 5'-GGA(G/C)(C/T)TC(A/G)(G/C)(A/T)GG(A/G)GCCAT GGA-3' was derived from a highly conserved 5' flanking nucleotide sequence of the rat (19), and guinea pig (unpublished data) CCK_B receptor cDNA. The 3' antisense primer (nucleotides 1431 to 1452; Fig. 1) were derived from the 3' noncoding region of the clone isolated from the human frontal cortex cDNA library described above. Each primer contained an additional 5' 9 bp cap and Xba I site (ACTGACTAGTCTA) necessary for subsequent ligation into the vector, pCDL-SRα at the Xba-1 restriction enzyme site.

DNA SEQUENCING: Both strands of the cDNA clones isolated from the human frontal cortex cDNA library and the product from PCR cloning from the human stomach cDNA were sequenced using the dsDNA Cycle Sequencing System (Bethesda Research Laboratory, Gaithersburg, MD).

DNA AND PROTEIN SEQUENCE ANALYSIS: The nucleotide and deduced amino acid sequences were analyzed by the Wisconsin Genetics Computer Group software package using the "Pileup" program (21).

NORTHERN BLOT ANALYSIS OF mRNAs: Approximately 2 μg of poly (A)⁺ RNA isolated by oligo dT cellulose chromatography were loaded in each lane and were separated electrophoretically on a 1.5% agarose/formaldehyde denaturing gel and blotted onto Nytran (Schleicher and Schuell, Keene, NH). The blot was hybridized with a [³²P] random prime labelled probe derived from the coding region of the human CCK_B receptor cDNA, and washed at high stringency (3 x 20' washes with 0.1 X SSC/0.1% SDS @ 42^o C). The blot was exposed for 48 hours and processed using a phosphorimager (Molecular Dynamics).

EXPRESSION of HUMAN CCK_B RECEPTOR cDNA IN MAMMALIAN CELLS: The product cloned by PCR amplification from human stomach fundus cDNA described above was digested with Xba I and ligated into the vector pCDL-SR α (22) at the Xba I site in the sense orientation. Two micrograms of vector plus insert were transfected into COS-7 cells ($\approx 1 \times 10^6$ cells per 100 mm tissue culture plate) using the DEAE/dextran method as described (23). Approximately 48 hours after transfection, the cells were washed in phosphate buffered saline (PBS; pH 7.4) containing bovine serum albumin (BSA) 1 mg/ml at 4 °C, scraped from the culture plate and suspended in Dulbecco's Modified Eagle Medium (DMEM) containing BSA 1 mg/ml, centrifuged (400X g), and suspended in the same medium at 4 °C ($\approx 300,000$ cells/ml). Suspended cells (500 μ l) were incubated for 60 minutes at 37 °C with 50 pM of [¹²⁵I]Bolton-Hunter-CCK-8 (2200 Ci/mmol) either with or without the indicated concentrations of unlabelled agonist or antagonist. Cells were subsequently washed three times at 4 °C with 2 ml PBS containing BSA 1 mg/ml at 4 °C and filtered on glass fibers filters (Whatman GF/A) using a suction manifold (Millipore, Bedford, MA). The filters were subsequently assayed for gamma radioactivity (Packard, Auto-Gamma).

CHROMOSOMAL MAPPING: Human chromosomal localization was performed using a somatic cell hybrid panel of human-hamster DNAs (BIOS Laboratories, New Haven, CT). Southern hybridization filters were generated from 25 specific hybrid DNA's (5 μ g each) digested with the restriction endonuclease Bam H1. The CCK_B receptor probe was then hybridized to these filters using a standard protocol at 65 °C with 3 X SSC. The final wash stringency was at 65 °C with 1 X SSC.

RESULTS AND DISCUSSION

Screening approximately 7.5×10^5 cDNA clones from a human frontal cortex cDNA library in the Lambda ZAP II vector resulted in the isolation of 44 clones that hybridized under low stringency to the rat CCK_B receptor probe. The longest plaque purified clone, 2.1 Kb, contained a nucleotide sequence that was 85% homologous to the rat CCK_B receptor cDNA. However, the clone contained an intron at the 5' end and did not contain the first 82 bases of the 5' coding region. The remaining sequence was obtained by PCR cloning from the human stomach fundus cDNA. Using the rat (19) and guinea pig (unpublished data) CCK_B receptor cDNA sequences a highly homologous 5' flanking sequence was identified for the design of a 64-fold degenerate sense primer with the following sequence: 5'-GGA(G/C)(C/T)TC(A/G)(G/C)(A/T)GG(A/G)GCCATGGA-3'. The 3' antisense primer, (5'-CAGGAAACCAACACCCAAAGC-3') was obtained from the 3' noncoding region of the clone isolated from the human frontal cortex cDNA library. PCR cloning from the human stomach fundus cDNA resulted in an ≈ 1.45 Kb product with an identical nucleotide sequence to the coding region of the clone isolated from the human frontal cortex cDNA and an additional 82 bp comprising the 5' coding sequence. This nucleotide sequence plus the 3' noncoding region of the human frontal cortex clone is 1969 bp in length (Fig. 1). The coding region sequence has approximately an 85% and 87% homology with the rat (19) CCK_B receptors and the canine parietal cell gastrin receptor (24) nucleotide coding region, respectively. This high degree of homology is in the expected range for interspecies variation in the same gene. This high degree of sequence homology between the rat and human CCK_B receptor and the canine gastrin receptor and the fact that the same CCK_B receptor cDNA has been cloned from human brain and stomach as well as the dog brain (unpublished data) and parietal cell (24) suggest that the CCK_B receptor and gastrin receptor are identical.

```

1 ATGGAGCTGCTCAAGCTGAACCGGAGCGTGCAGGGAACCGGACCCGGCCGGGGCTCCCTGTCCGCGCCGGG 75
  MetGluLeuLeuLysLeuAsnArgSerValGlnGlyThrGlyProGlyProGlyAlaSerLeuCysArgProGly 25
76 GCGCCTCTCCTCAACAGCAGTGTGGGCAACCTCAGCTGCGAGCCCTCGATTGCGGGAGCCGGGACACGA 150
26 AlaProLeuLeuAsnSerSerValGlyAsnLeuSerCysGluProProArgIleArgGlyAlaGlyThrArg 50
151 GAATTGGAGCTGGCCATTAGAATCACTCTTTACGCAGTGTCTTCTGATGAGCGTTGGAGAAATATGCTCATC 225
51 GluLeuGluLeuAlaIleArgIleThrLeuTyrAlaValIlePheLeuMetSerValGlyGlyAsnMetLeuIle 75
226 ATCGTGGCTCTGGGACTGAGCCCGCCCTGAGGACTGTCCACCAATGCTTCCTCCTCCTACTGGCAGTCAGCCG 300
76 IleValValLeuGlyLeuSerArgArgLeuArgThrValThrAsnAlaPheLeuLeuSerLeuAlaValSerAsp 100
301 CTCCTGCTGGCTGTGGCTTGCATGCCCTTCAACCTCCTGCCAATCTCATGGGCACATTCATCTTTGGCCCGTC 375
101 LeuLeuLeuAlaValAlaCysMetProPheThrLeuLeuProAsnLeuMetGlyThrPheIlePheGlyThrVal 125
376 ATCTGCAAGGCGGTTTCCTACCTCATGGGGTGTCTGTGAGTGTGCCAGCTAAGCCTCGTGGCCATCGCACTG 450
126 IleCysLysAlaValSerTyrLeuMetGlyValSerValSerValSerThrLeuSerLeuAlaIleAlaLeu 150
451 GAGCGGTACAGCCCATCTCCGACCCTGCAGGCAGAGTGTGGCAGACGGCTCCACCGGGCTCGCGTGATT 525
151 GluArgTyrSerAlaIleCysArgProLeuGlnAlaArgValTrpGlnThrArgSerHisAlaAlaArgValIle 175
526 GTAGCCACGTGGTGTGCTCCGACTACTCATGGTCCCTACCCCGTACACTGCTGTGCAACAGCTGGGGCT 600
176 ValAlaLeuTrpLeuSerGlyLeuLeuMetValProTyrProValTyrThrValValGluProValGlyPro 200
601 CGTGTGCTGCAGTGGCGCATCGCTGGCCAGTGGCCGGTCCGCCAGACCTGGTCCGCTACTGCTGCTTCTGCT 675
201 ArgValLeuGlnCysValHisArgTrpProSerAlaArgValArgGlnThrTrpSerValLeuLeuLeuLeu 225
676 TTGTCTTCTACCCGGGTGTGGTATGGCCGTGGCCCTACGGCTTATCTCTCGCAGCTTACTTAGGGCTTCGC 750
226 LeuPhePheIleProGlyValValMetAlaValAlaTyrGlyLeuIleSerArgGluLeuTyrLeuGlyLeuArg 250
751 TTTGACGGCGCAGTGACAGCCAGCCAAAGCAGGGTCCGAAACCAAGCGGGCTGCCAGGGGCTGTTCCACC 825
251 PheAspGlyAspSerAspSerGlnSerArgValArgAsnGlnGlyGlyLeuProGlyAlaValHisGln 275
826 AACGGCGGTTGCCGCGCTGAGACTGGCCGGTGGCGAAGACAGCGATGGCTGCTACGTGCAACTTCCACGTTCC 900
276 AsnGlyArgCysArgProGluThrGlyAlaValGlyGluAspSerAspGlyCysTyrValGlnLeuProArgSer 300
901 CGGCCTGCCTGGAGCTGACGGCGCTGACGGCTCCTGGCCGGGATCCGGCTCCCGGCCACCCAGGCCAAGCT 975
301 ArgProAlaLeuGluLeuThrAlaLeuThrAlaProGlyProGlySerGlySerArgProThrGlnAlaLysLeu 325
976 CTGGCTAAGAAGCGGTGGTGCGAATGTTGCTGCTGATCGTGTGCTTTTCTGTGTTGGTGGCCAGTTTAT 1050
326 LeuAlaLysLysArgValValArgMetLeuLeuValIleValValLeuPhePheLeuCysTrpLeuProValTyr 350
1051 AGTGCCAAACGTTGGCGGCCCTTGTATGGCCGGGTGCACACCGAGCAGCTCTCGGGTCTCCTATGCTCCTTCA 1125
351 SerAlaAsnThrTrpArgAlaPheAspGlyProGlyAlaHisArgAlaLeuSerGlyAlaProIleSerPheIle 375
1126 CACTGTCTGAGCTACGCTCGGCTGTGCAACCCCTGGTCTACTGCTTCAATGCACCGTGGCTTTCGCCAGGGC 1200
376 HisLeuLeuSerTyrAlaSerAlaCysValAsnProLeuValTyrCysPheMetHisArgArgPheArgGlnAla 400
1201 TGCTGGAAACTTGGCGCTGCTGCTGCCCCGGCCCTCCACGAGCTGGCCCGAGGGCTCTCCGATAGGACCT 1275
401 CysLeuGluThrCysAlaArgCysCysProArgProProArgAlaArgProArgAlaLeuProAspGluAspPro 425
1276 CCCACTCCCTCCATTGCTTCGCTGTCCAGGCTTAGCTACACCACCATCAGCACACTGGGCCCTGGCTGAGGAT 1350
426 ProThrProSerIleAlaSerLeuSerArgLeuSerTyrThrThrIleSerThrLeuGlyProGlyEnd 447
1351 GAGGGCGCTGGGGTGTAGGCAGGGCAATGACATGCACCTGACCCCTCCAGACATAGAAAACCAAACCAAC 1425
1426 TGACACAGGAAACCAACACCCAAAGCATGGACTAACCCCAACGACAGGAAAAGGTAGCTTACCTGACACAAGAGG 1500
1501 AATAAGAAATGGAGCAGTACATGGGAAAGGAGGCATGCCTCTGATATGGGACTGAGCTGGCCATAGAAAACATGA 1575
1576 CACTGACCTTGGAGAGACACAGCGCTCCCTAGCAGTGAATTTCTACACAGTGGCAACTCTGACAGGGCTGAC 1650
1651 CTGGCTCTCACACACATAGATTAAATGGCACTGATTGTTTTAGAGACTATGGAGCTGGCACAGGACTGACTCTGG 1725
1726 GATGCTCTAGTTTACCTCAGATGACCTTCCCAATCAGCACTGAAATACCATCAGGCCTAATCTCATACCT 1800
1801 CTGACCAAGCGCTGTTCTGCACTGAAAAGTCTTCATCCCTTCCAGTTAAGGACCTGGCCCTGCCCTCCTCC 1875
1876 TTCCTCCAAACTGTTCAGAAATATAAATTTGTTGGCTCTCTGAAAAAATAAAAAAAAAAAAAAAAAAAAA 1950
1951 AAAAAAAAAAAGGAATTC 1969

```

FIG. 1. Nucleotide and deduced amino acid sequences of the human brain and stomach CCK_B receptor cDNA clone. The solid lines labelled with Roman numerals I-VII delineate the putative transmembrane domains predicted by the Kyte-Doolittle criteria (31) and homology with the rat CCK_B as well as other G-protein-coupled receptor superfamily members. The solid triangles indicate three potential sites for N-linked glycosylation. The solid underlines indicate potential sites for serine and threonine phosphorylation (25). The AATAAA cleavage and polyadenylation sequence is underlined. Solid circles indicate cysteine residues which are potential sites for either disulfide bridge formation (26,27,28) (residues 127 and 205) or palmitoylation (29,30) (residue 408).

The nucleotide sequence contains a single long open reading frame which encodes for a unique 447 amino acid protein with a calculated molecular mass of ≈ 48.5 kDa. The receptor is 5 and 6 amino acids less than the rat CCK receptor and canine parietal cell gastrin receptor (24) respectively, principally, because of a loss of a block of 5 amino acids in the third intracellular loop (Fig. 2). The sequence allows for three potential N-linked glycosylation sites, all in the amino terminus (Fig. 1). The number of potential N-linked glycosylation sites is similar to that published for dog (24) and is less than that reported for the rat (19). There are two potential sites for protein

```

HUCCCKBR  MELLKLNRSV QGTGPGGAS LCRPGAPLLN SSSVGNLSCE PPRIRGAGTR ELELAIRITL YAVIFLMSVG GMLLIIVVLG LSRRRLRTVN AFLLSLAVSD 100
RTCCCKBR  MELLKLNRSV QGTGPGGAS LCRPGAPLLN SSSVGNLSCE PPRIRGAGTR ELELAIRITL YAVIFLMSVG GMLLIIVVLG LSRRRLRTVN AFLLSLAVSD 100
CANGASR   MELLKLNRSV QGTGPGGAS LCRPGAPLLN SSSVGNLSCE PPRIRGAGTR ELELAIRITL YAVIFLMSVG GMLLIIVVLG LSRRRLRTVN AFLLSLAVSD 100

HUCCCKBR  LLLAVACMPF TLLPNLMGTF IFGTVICKAV SYLMGVSVSV STLSLVAIAL ERYSAICRPL QARVWQTRSH AARVIVATWL LSGLLMVYPY VYTVVQPV.VG 199
RTCCCKBR  LLLAVACMPF TLLPNLMGTF IFGTVICKAV SYLMGVSVSV STLSLVAIAL ERYSAICRPL QARVWQTRSH AARVIVATWL LSGLLMVYPY VYTVVQPV.VG 199
CANGASR   LLLAVACMPF TLLPNLMGTF IFGTVICKAV SYLMGVSVSV STLSLVAIAL ERYSAICRPL QARVWQTRSH AARVIVATWL LSGLLMVYPY VYTVVQPV.VG 200

HUCCCKBR  PRVLQCVHRW PSARVRQTWS VLLLLLFFI PGVMAVAYG LISRELYLGL RFDGSDSDS QSRVRNQGGL PGA.....VH QNGRCRPETG AVGEDSDGCG 294
RTCCCKBR  PRVLQCVHRW PSARVRQTWS VLLLLLFFI PGVMAVAYG LISRELYLGL RFDGSDSDS QSRVRNQGGL PGGAAPGVH QNGRCRPETG AVGEDSDGCG 299
CANGASR   PRVLQCVHRW PSARVRQTWS VLLLLLFFI PGVMAVAYG LISRELYLGL RFDGSDSEI .SRVRNQGGL RGGAGPGAPV QNGRCRPETG AVGEDSDGCG 298

HUCCCKBR  VQLPRSRPAL ELTALTAPGP G..SGSRPTQ AKLLAKKRVV RMLLVIVVLF FLCWLPVYSA NTVRAFDGPG AHRALSGAPI SFIHLLSYAS ACVNPLVYCF 392
RTCCCKBR  VQLPRSRPAL ELTALTAPGP G..SGSRPTQ AKLLAKKRVV RMLLVIVVLF FLCWLPVYSA NTVRAFDGPG AHRALSGAPI SFIHLLSYAS ACVNPLVYCF 397
CANGASR   VQLPRSRPAL ELTALTAPGP G..SGSRPTQ AKLLAKKRVV RMLLVIVVLF FLCWLPVYSA NTVRAFDGPG AHRALSGAPI SFIHLLSYAS ACVNPLVYCF 398

HUCCCKBR  MHRRFRQACL ETCARCCPRP PRARPRALPD EDPPTPSIAS LSRLSYTTIS TLPGP* 447
RTCCCKBR  MHRRFRQACL ETCARCCPRP PRARPRALPD EDPPTPSIAS LSRLSYTTIS TLPGP* 452
CANGASR   MHRRFRQACL ETCARCCPRP PRARPRALPD EDPPTPSIAS LSRLSYTTIS TLPGP* 453

```

FIG. 2. Alignment of the human CCK_B receptor (HUCCCKBR), rat CCK_B receptor (RATCCCKBR) and canine gastrin receptor (CANGASR) deduced protein sequences. Using the "Pileup" program sequence analysis package of the Genetics Computer Group (21) the human CCK_B receptor was aligned for maximal homology with the rat CCK_B receptor and the canine gastrin receptor. Shown here using amino acid letter symbols is the result of this alignment with solid lines indicating putative transmembrane domains and boxed letters indicating amino acids from rat and dog not conserved in the human receptor sequence.

kinase C phosphorylation (25) on serines in the first and third intracellular loop (residues 82 and 300, Fig. 1) and three potential sites for protein kinase A phosphorylation on serines in the second intracellular loop and amino terminus (residues 154 and 437) and on threonine in the third intracellular loop (residue 321; Fig.1) (25). A comparison of the amino acid sequence of the human CCK_B receptor with rat CCK_B receptor (19) and canine gastrin receptor (24) shows an ≈ 90% identity, with the highest degree of homology in the transmembrane domains and the least degree of homology in the amino and carboxy termini and the third intracellular loop (Fig. 2). Similar to the rat CCK_B receptor (19) and the canine gastrin receptor (24), there are conserved cysteines in the first and second extracellular loops which may form a disulfide bridge (residues 107, 157; Fig. 2) required for stabilization of the tertiary structure as demonstrated for rhodopsin(26), β-adrenergic (27), and muscarinic receptors (28). A cysteine in the carboxy-terminus (residue 408; Fig.2) may be a membrane anchoring palmitoylation site similar to rhodopsin and the β-adrenergic receptors (29,30).

A hydropathy plot (data not shown) using the criteria of Kyte and Doolittle (31) and homology with other G-protein-coupled receptor superfamily members identifies seven regions of hydrophobic residues corresponding to putative transmembrane domains expected for members of the G-protein-coupled superfamily of receptors (32,33).

High stringency northern blot analysis of 2 μg of organ specific polyadenylated mRNA reveals that the CCK_B receptor cDNA full-coding-region probe hybridizes to predominantly a 2.8 Kb transcript and to a lesser degree to a 3.3 Kb transcript in stomach fundus, pancreas, and gallbladder. However, in the brain, the probe hybridizes equally to both transcripts (Fig. 3). This transcript size is similar in size to the 2.7 Kb size reported in rats (19), and is larger than the canine gastrin transcript (approximately 2.1 Kb) (24). Both bands were present in all of the tissues expressing transcripts after high stringency washing suggesting that they are probably transcripts




FIG. 3. Northern blot analysis of poly (A)⁺ RNA from the human organs. Two micrograms of poly (A)⁺ RNA from human brain, stomach, pancreas, and gallbladder were separated on a 1.5% denaturing/formaldehyde agarose gel and probed under conditions of high stringency with the coding region of the CCK_B receptor cDNA labelled with [³²P] by random primer extension. The blot was exposed for 48 hours and scanned with a phosphorimager (Molecular Dynamics). The lines on the left correspond to the migration positions of the 28S and 18S ribosomal RNA.

from the same gene. The presence of a strongly hybridizing band in human gallbladder is not surprising given that the guinea pig gallbladder has been shown previously to possess CCK_B receptors (12).

We used the CCK_B receptor cDNA as a [³²P]random prime labelled probe to hybridize to a blot of human-hamster chromosomal hybrid DNA's cut with Bam H1. The presence of an 11 Kb hybridizing fragment in both the hybrid 1049 and the parental human control indicates that the CCK_B receptor maps to chromosome 11. Further localization studies will allow more specific mapping of the CCK_B receptor gene on chromosome 11.

To confirm that the CCK_B receptor clone isolated from both human brain and stomach encodes for a functional CCK_B receptor, and to demonstrate for the first time, the precise pharmacology of a pure human CCK_B receptor, ligand binding dose-inhibition studies were performed. The human CCK_B receptor cDNA obtained from PCR cloning (1.45 Kb insert) was cloned into the Xba I site of the mammalian expression vector, pCDL-SR α , and transfected into COS-7 cells using DEAE/dextran. Radioligand binding studies using [¹²⁵I]-BH-CCK-8 alone or in the presence of increasing concentrations of either unlabelled CCK receptor agonists or antagonists were performed. These studies showed that [¹²⁵I]-BH-CCK-8 binding inhibition by CCK-8 ($EC_{50} = 3 \times 10^{-9}$ nM) was 2-fold more potent than gastrin-17-I ($EC_{50} = 6.4 \times 10^{-9}$ nM) and inhibition by the CCK_B receptor antagonist, L-365,260 ($EC_{50} = 1 \times 10^{-8}$ nM) was 50-fold more potent than the CCK_A receptor specific antagonist L-364,718 ($EC_{50} = 5 \times 10^{-7}$ nM)(Fig. 4). These findings are similar to that reported previously for native rat CCK_B receptors (34), in the transformed human T-lymphocyte, JURKAT cells (15), and in a human small cell carcinoma cell line (14). These results differ significantly from the results reported for the canine gastrin receptor




FIG. 4. Ability of CCK receptor agonists and antagonists to inhibit binding of [125 I]BH-CCK-8 to COS-7 cells expressing the human CCK_B receptor. COS-7 cells were transfected with the mammalian expression vector, pCDL-SR α , containing the human CCK_B receptor cDNA. Transfected COS-7 cells were incubated with either the tracer alone or increasing concentrations of agonists CCK-8 or gastrin-17-I (left panel) or antagonists L-365,260 and L-364,718 (right panel). Data are presented as percent saturable binding (total binding in the presence of labelled hormone alone minus binding in the presence of 1 μ M CCK-8).

(24). The canine parietal cell gastrin receptor has almost a 7-fold greater affinity for the CCK_A receptor antagonist L-364,718 than for the gastrin receptor antagonist L-365,260 (24). This divergence in canine gastrin receptor reversal in affinity for the antagonist L-364,718 and L-365,260 (6).

In the present study we have, using the previously cloned rat CCK_B receptor DNA sequence as a probe, cloned from both a human brain cDNA library and from human gastric fundus the human CCK_B receptor DNA. The DNA sequence is 90 percent homologous to the rat and dog sequences. Expression of the cloned DNA gives binding characteristics similar to the rat CCK_B but different to the dog. Furthermore, we show that the brain and stomach CCK_B receptors are identical. These results will enhance our understanding of the central nervous system and gastrointestinal CCK_B receptor and permit the introduction of specific agonists and antagonists to this receptor. This will be useful for the elucidation of the mechanisms of various neuropsychiatric diseases and will hasten the treatment of disorders such as anxiety, and panic disorders as well as schizophrenia.

REFERENCES

- Hill, D.R., Campbell, N.J., Shaw, T.M., and Woodruff, G.N. (1987) *J. Neurosci.* 7, 2967-2976.
- Jensen, R.T., Wank, S.A., Rowley, W.H., Sato, S., and Gardner, J.D. (1989) *Trends Pharmacol. Sci.* 10, 418-423.
- Saito, A., Sankaran, H., Goldfine, I.D., and Williams, J.A. (1980) *Science* 1155-1156.
- Moran, T.H., Robinson, P.H., Goldrich, M.S., and McHugh, P.R. (1975) *Brain Research* 362, 986-989.

5. Chang, R.S.L., and Lotti, V.J. (1986) *Proc. Natl. Acad. Sci.* 83, 4923-4926.
6. Lotti, V.J., and Chang, R.S.L. (1989) *Eur. J. Pharm.* 162, 273-280.
7. Crawley, J.N. (1991) *Trends Pharm. Sci.* 12, 232-236.
8. Singh, L., et. al. (1991) *Proc. Natl. Acad. Sci.* (1991) 88, 1130-1133.
9. Wisenfeld-Hullin, Z., et. al. (1990) *Proc. Natl. Acad. Sci.* 87, 7105-7109.
10. Sandvik, A.K., and Waldum, H.L. (1991) *Am. J. Physiol.* 260, G925-G928.
11. Lin, C.W., et. al. (1992) *Am. J. Physiol.* 262, G1113-G1120.
12. Grider, J.R., and Makhlouf, G.M. (1990) *Am. J. Physiol.* 259, G184-G190.
13. Singh, P., et.al. (1991) *Am. J. Physiol* 249, G761-G769.
14. Staley, J., Jensen, R.T., and Moody, T.W. (1990) *Peptides* 11, 1033-6.
15. Lignon, M., Bernad, N., and Martinez, J. (1991) *Mol. Pharm.* 39, 615-620.
16. Weinstock, J., and Baldwin, G.S. (1988) *Cancer Research* 48, 932-937.
17. Pearson, R.K., Hadac, M., and Miller, L.J. (1989) *Am. J. Physiol.* 256, G1005-1010.
18. Chicone, L., Narayan, S., Townsend, C.M., and Singh, P. (1989) *Biochem. Biophys. Res. Comm.* 164, 512-519.
19. Wank, S.A., Piseigna, J.R., and deWeerth, A. (1992) *Proc. Natl. Acad. Sci. USA.* 89, 8691-8695.
20. Han, J.H., Stratowa, C., and Rutter, W.J. (1987) *Biochem.* 26, 1617-25.
21. Devereaux, J., Haebri, P., and Smithies, O. (1984) *Nuc. Acids Res.* 12, 387-395.
22. Takebe, Y., et. al. (1988) *Mol. Cell. Biol.* 8, 466-472.
23. Cullen, B.R. (1987) *Methods Enzymol.* 152, 684-704.
24. Kopin, A.S., et. al. (1992) *Proc. Natl. Acad. Sci. USA.* 89, 3605-3609.
25. Kennelly, P.J., and Krebs, E.G. (1991) *J. Biol. Chem.* 15555-15558.
26. Karnik, S.S., et. al. (1988) *Proc. Natl. Acad. Sci. USA.* 85, 8459-8463.
27. Dixon, R.A., et. al. (1987) *EMBO. J.* 6, 3269-3275.
28. Hulme, E.C., Birdsall, N.J., and Buckley, N.J. (1990) *Ann. Rev. Pharmacol.*
29. O'Dowd, B., et. al. (1989) *J. Biol. Chem.* 264, 7564-7569.
30. Ovchinnikov, Y.A., Abdulaev, N.G., and Bogachuk, A.S. (1988) *FEBS Lett.* 230, 1-5.
31. Kyte, J., and Doolittle, R.R. (1982) *J. Mol. Biol.* 157, 105-132.
32. Lambert, M., Bui, N.D., and Christophe, J. (1991) *Reg. Pep.* 322, 151-167.
33. Merrit, J.E., Taylor, C.W., Rubin, R.P., and Putney, J.W. (1986) *Biochem. J.* 236, 337-343.
34. Jensen, R.T., Huang, S.C., von Schrenck, T., Wank, S.A., and Gardner, J.D. (1990) in *GI Endocrinology: Receptors and Post-Receptor Mechanisms* (Thompson, J.T., Townsend, C.M., Greeley, G.A., Rayford, P.L., Jr., Cooper, C.W., Singh, P.O., and Rubin, N., Ed.) pp. 95-113. Academic Press, New York, N.Y.